Protalix BioTherapeutics, Inc. (PLX)
ASE · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 17.9M | 9.1M | 33.8M | 19.9M |
| Gross Profit | 9.5M | 4.5M | 29.6M | 12.1M |
| Operating Income | 2.1M | (4.7M) | 21.1M | 4.7M |
| Net Income | 2.4M | (5.5M) | 18.3M | 3.8M |
| Diluted EPS | $0.03 | N/A | $0.22 | $0.05 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 47.6M | 65.5M | 53.4M | 52.7M |
| Gross Profit | 28.0M | 42.5M | 29.1M | 25.8M |
| Operating Income | (13.0M) | 10.5M | 3.9M | (5.5M) |
| Net Income | (14.9M) | 8.3M | 2.9M | (6.6M) |
| Diluted EPS | $-0.31 | $0.09 | $0.04 | $-0.08 |